BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 37026918)

  • 1. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel cuproptosis-related prognostic gene signature in adrenocortical carcinoma.
    Gao W; He X; Huangfu Q; Xie Y; Chen K; Sun C; Wei J; Wang B
    J Clin Lab Anal; 2023 Nov; 37(21-22):e24981. PubMed ID: 37997497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
    Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
    Front Immunol; 2022; 13():974034. PubMed ID: 36203594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and potential immune involvement of cuproptosis in kidney renal clear cell carcinoma.
    Liu H
    Cancer Genet; 2023 Jun; 274-275():21-25. PubMed ID: 36963335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
    Bian Z; Fan R; Xie L
    Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell senescence regulator p16 is a promising cancer prognostic and immune check-point inhibitor (ICI) therapy biomarker.
    Tu Z; Wang X; Cai H; Sheng Y; Wu L; Huang K; Zhu X
    Aging (Albany NY); 2023 Mar; 15(6):2136-2157. PubMed ID: 36961395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
    Yang Q; Zeng S; Liu W
    PeerJ; 2023; 11():e15019. PubMed ID: 36949759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model.
    Wan H; Yang X; Sang G; Ruan Z; Ling Z; Zhang M; Liu C; Hu X; Guo T; He J; Liu D; Pei J
    Aging (Albany NY); 2023 Oct; 15(20):11244-11267. PubMed ID: 37857018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma.
    Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH
    Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
    Song S; Zhang M; Xie P; Wang S; Wang Y
    Front Immunol; 2022; 13():978909. PubMed ID: 36341328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across¬†multiple¬†cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-Related Ferroptosis genes for Predicting Prognosis in kidney renal clear cell carcinoma.
    Luo G; Wang L; Zheng Z; Gao B; Lei C
    Eur J Med Res; 2023 May; 28(1):176. PubMed ID: 37189176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis.
    Qin Y; Liu Y; Xiang X; Long X; Chen Z; Huang X; Yang J; Li W
    Mol Cancer; 2023 Mar; 22(1):59. PubMed ID: 36959665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.